EGFR and glioblastoma: In glioblastoma (GBM), DYRK1A was found to be highly expressed in EGFR-amplified tumors, whereas doxycyclin-inducible shRNA depletion of DYRK1A decreased tumor growth in the orthotopic xenograft models (Pallavicini et al., 2019).